Skip to Content
Last Updated: 04/25/2012

Definitive, Late Phase Trials

Phase 3 Trial in Advanced Non-Small Cell Lung Cancer Will Assess FDG-PET/CT as Predictive Marker of Response and Patient Outcome

ACRIN is conducting a study, ACRIN 6678, to prospectively validate FDG-PET in conjunction with computed tomography (CT) as a predictive marker of response and patient outcome in patients with advanced NSCLC. This study was activated in March 2007 and is the result of a joint effort between CTEP, DCTD’s CIP, the FDA, and the Centers for Medicare and Medicaid under the Oncology Biomarker Qualification Initiative. This study may have an impact on how new targeted therapies are applied to patients with lung cancer.

About the
Associate Director

Jeffrey S. Abrams, M.D. Jeffrey S. Abrams, M.D., has led the Cancer Therapy Evaluation Program (CTEP) since June 2007.  Dr. Abrams came to CTEP in 1993 when he joined as a clinical research scientist to oversee the breast cancer treatment trials portfolio and participate in clinical trials at the NIH Clinical Center and the National Naval Medical Center. More…

For More Details
About CTEP